Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from iTeos Therapeutics ( (ITOS) ).
On August 29, 2025, iTeos Therapeutics completed a merger with Concentra Biosciences, resulting in iTeos becoming a wholly owned subsidiary of Concentra. The merger was executed without requiring a stockholder vote, and as a result, iTeos’ shares were delisted from Nasdaq, marking a significant change in the company’s market presence and operational structure.
The most recent analyst rating on (ITOS) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on iTeos Therapeutics stock, see the ITOS Stock Forecast page.
Spark’s Take on ITOS Stock
According to Spark, TipRanks’ AI Analyst, ITOS is a Neutral.
iTeos Therapeutics’ overall stock score is driven by serious financial and valuation concerns, despite a favorable technical position and potential benefits from corporate events. The merger announcement offers some optimism, but strategic challenges and negative financials weigh heavily.
To see Spark’s full report on ITOS stock, click here.
More about iTeos Therapeutics
iTeos Therapeutics, Inc. operates in the biotechnology industry, focusing on the development of immuno-oncology therapeutics. The company is primarily engaged in creating innovative cancer treatments that harness the body’s immune system to combat cancer cells.
Average Trading Volume: 1,341,933
Technical Sentiment Signal: Hold
Current Market Cap: $448.7M
See more insights into ITOS stock on TipRanks’ Stock Analysis page.